DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Cytopathic effect (CPE) assay are 234

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0047	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28912011
DrugRepV_0049	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28912011
DrugRepV_0052	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0053	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0058	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0059	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0062	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0063	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0075	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0078	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0081	Avonex	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0084	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0087	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0090	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	28185815
DrugRepV_0748	Favipiravir	Antiviral	Influenza virus	Nipah virus	rNiV-Gluc-eGFP	NA	Cytopathic effect (CPE) assay	Decrease (4 Log (pfu/ml))	Investigational	29765101
DrugRepV_1992	Emetine Dihydrochloride Hydrate	Antiparasitic products, Insectisides and Repellents	Protozoal disease	Middle East respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24841273
DrugRepV_1993	Chloroquine Diphosphate	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_1994	Hydroxychloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_1995	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	24841273
DrugRepV_1996	Amodiaquine Dihydrochloride dihydrate	Antiparasitic products, Insectisides and Repellents	Malaria	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	24841273
DrugRepV_1997	Gemcitabine Hydrochloride	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_1998	Tamoxifen Citrate	Antineoplastic and Immunomodulating Agents	Breast cancer	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_1999	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	24841273
DrugRepV_2000	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2001	Anisomycin	Antibacterial	Bacterial infections	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	24841273
DrugRepV_2002	Cycloheximide	Antibacterial	Bacterial and fungal infections	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24841273
DrugRepV_2003	Benztropine Mesylate	Nervous System	Parkinson disease	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2004	Fluspirilene	Nervous System	Schizophrenia	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	24841273
DrugRepV_2005	Thiothixene	Nervous System	Schizophrenia	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2006	Fluphenazine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2007	Promethazine Hydrochloride	Respiratory System	Allergic disorders | Nausea/vomiting	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	24841273
DrugRepV_2008	Astemizole	Respiratory System	Allergies	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Withdrawn	24841273
DrugRepV_2009	Chlorphenoxamine Hydrochloride	Respiratory System	Parkinson's	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Withdrawn	24841273
DrugRepV_2010	Chlorpromazine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2011	Triflupromazine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2012	Clomipramine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2013	Imatinib Mesylate	Antineoplastic and Immunomodulating Agents	Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2014	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (90 %)	Approved	24841273
DrugRepV_2128	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27163257
DrugRepV_2130	Favipiravir	Antiviral	Influenza virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27163257
DrugRepV_2132	2-C-Methylcytidine	NA	Hepatitis C virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	27163257
DrugRepV_2134	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	27163257
DrugRepV_2140	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2142	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2144	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2146	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2148	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2150	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2152	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2154	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_3156	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	14670584
DrugRepV_3157	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3158	Glycyrrhizin	Alimentary Tract and Metabolism	Chronic hepatitis	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Experimental	14670584
DrugRepV_3159	Iota-carrageenan	Plant extract	Common Cold	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	14670584
DrugRepV_3160	Fucoidan	NA	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3161	Dextran Sulphate	Blood and Blood Forming Organs	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	14670584
DrugRepV_3162	IFN-alpha2a	Antineoplastic and Immunomodulating Agents	Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	14670584
DrugRepV_3163	IFN-alpha2b	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	14670584
DrugRepV_3164	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (1.8 Log)	Approved	14670584
DrugRepV_3165	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (1.8 Log)	NA	14670584
DrugRepV_3166	Glycyrrhizin	Alimentary Tract and Metabolism	Chronic hepatitis	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (5.2 Log)	Approved, Experimental	14670584
DrugRepV_3167	IFN-alpha2b	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (5.4 Log)	Approved	14670584
DrugRepV_3168	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	Approved	14670584
DrugRepV_3169	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	NA	14670584
DrugRepV_3170	Glycyrrhizin	Alimentary Tract and Metabolism	Chronic hepatitis	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	Approved, Experimental	14670584
DrugRepV_3171	IFN-alpha2b	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	Approved	14670584
DrugRepV_3172	IFN-alpha2b-Ribavirin	NA	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3261	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3262	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3263	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3264	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3265	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3266	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3267	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3268	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3269	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3270	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3271	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3272	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3363	Peg-interferon A-2b	Antineoplastic and Immunomodulating Agents	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	HKU-39849	NA	Cytopathic effect (CPE) assay	Decrease (100 %)	Approved	23620378
DrugRepV_3364	Peg-interferon A-2b	Antineoplastic and Immunomodulating Agents	Hepatitis C virus	Middle East respiratory syndrome coronavirus	HKU-39849	NA	Cytopathic effect (CPE) assay	Decrease (100 %)	Approved	23620378
DrugRepV_3431	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Hongkong/4801/2014 (H3N2)		Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3737	OSU-03012	Anticancer	Brain cancer	Crimean-Congo hemorrhagic fever virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25986249
DrugRepV_3861	Favipiravir	Antiviral	Influenza virus	Rift Valley fever virus	MP12	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27736754
DrugRepV_3867	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3868	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3869	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3870	BCX4430	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3871	BCX4430	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3872	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3873	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3874	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3875	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3876	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3877	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3878	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3879	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3880	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3881	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3882	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_4190	Phorbol	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4191	Phorbol-12-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	25970561
DrugRepV_4192	Phorbol-12-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4193	Phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4194	Phorbol-13-butyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4195	Pphorbol-13-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4196	Phorbol-13-tetradecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4197	Phorbol-12,13-diacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4198	Phorbol-12,13-dibutyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4199	Phorbol-12,13- dihexanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4200	Phorbol-12,13-didecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4201	4α-phorbol-12,13-didecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4202	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase II	25970561
DrugRepV_4203	12-O-tetradecanoyl-4?-phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4204	12-O- tiglylphorbol-13-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4205	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4206	Phorbol-13,20-diacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4207	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4208	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4209	Phorbol-12,13,20-triacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4210	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4211	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4212	12-deoxyphorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4213	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4214	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4215	Ingenol	Dermatologicals	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4216	Ingenol-3-mebutate	Dermatologicals	Actinic keratosis	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	25970561
DrugRepV_4217	Ingenol-3,20-dibenzoate	Dermatologicals	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4218	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	25970561
DrugRepV_4219	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	25970561
DrugRepV_4576	Glycyrrhizin	Alimentary Tract and Metabolism	Chronic hepatitis	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Experimental	15715493
DrugRepV_4577	Glycyrrhetinic Acid	NA	Apparent mineralocorticoid excess syndrome	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	15715493
DrugRepV_4578	(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4579	(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4580	(2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[({[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}methyl)carbamoyl]-3-({3,4,5-trihydroxy-6-[({[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}methyl)carbamoyl]oxan-2-yl}oxy)oxan-2-yl}oxy)-2,4a,6a,6b,9,9,12a-heptame	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4581	6-{[(3S,6aR,6bS,8aS,11S,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-{[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-3,4-dihydroxy-N-[(2S)-4-methyl-1-oxopentan-2-yl]-5-[(3	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4582	butyl (2S)-2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-1-butoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}-3-[(6-{[(2S)-1-butoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4583	methyl (2S)-2-(2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[({[(2S)-1-methoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]-3-({3,4,5-trihydroxy-6-[({[(2S)-1-methoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]oxan-2-yl}oxy)oxan	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4584	(4S)-4-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-4-carboxy-1-oxobutan-2-yl]carbamoyl}-3-[(6-{[(2S)-4-carboxy-1-oxobutan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4585	butyl (2S)-2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-1-butoxy-1-oxopropan-2-yl]carbamoyl}-3-[(6-{[(2S)-1-butoxy-1-oxopropan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4586	(2S,4aS,6aS,6bR,10S,12aS)-10-{[4,5-dihydroxy-6-(2-hydroxyacetyl)-3-{[3,4,5-trihydroxy-6-(2-hydroxyacetyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carbo	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4587	(2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[(6-oxo-2-sulfanylidene-1,2,3,6-tetrahydropyrimidin-4-yl)carbamoyl]-3-({3,4,5-trihydroxy-6-[(6-oxo-2-sulfanylidene-1,2,3,6-tetrahydropyrimidin-4-yl)carbamoyl]oxan-2-yl}oxy)oxan-2-yl}oxy)-2,4a,6a,6b,9,9,1	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4588	5-{6-[(2-{[(3S,6aR,6bS,8aS,11S,14bS)-11-(2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-6-(2,4-dioxo-1,2,3,4-tetrahydropyrimidi	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4589	methyl (2S,4aS,6aS,6bR,10S,12aS)-10-({6-[(hydrazinecarbonyl)carbonyl]-3-({6-[(hydrazinecarbonyl)carbonyl]-3,4,5-trihydroxyoxan-2-yl}oxy)-4,5-dihydroxyoxan-2-yl}oxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4590	methyl (2S,4aS,6aS,6bR,10S,12aS)-10-{[6-(2-azidoacetyl)-3-{[6-(2-azidoacetyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-ca	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4591	2-{[(6aR,6bS,8aS,11S,14bS)-11-(acetyloxy)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4592	4-{[(6aR,6bS,8aS,11S,14bS)-11-(acetyloxy)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-4-oxobutanoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4614	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	19853271
DrugRepV_4615	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	19853271
DrugRepV_4616	Promazine	Nervous System	Psychomotor agitation	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Vet approved	19853271
DrugRepV_4617	Promazine	Nervous System	Psychomotor agitation	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Vet approved	19853271
DrugRepV_4618	Calpain VI inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4619	Calpain VI inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4620	Calpain IV inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4621	Calpain IV inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4622	Infergen	Anticancer	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcom	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	19853271
DrugRepV_4623	Infergen	Anticancer	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcom	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	19853271
DrugRepV_4624	Ampligen	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4625	Ampligen	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4626	UDA	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4627	UDA	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4628	EP128533	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4629	EP128533	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4634	TG-0205221	NA	SARS coronavirus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4635	ethyl (2E,4S)-4-[(2S)-3-(4-fluorophenyl)-2-[(2S)-3-methyl-2-[(5-methyl-1,2-oxazol-3-yl)formamido]butanamido]propanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4636	ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-3-phenylpropanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4637	ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4638	ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-(tert-butoxy)butanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4639	TG-0205221	NA	SARS coronavirus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (6.4 Log10)	NA	16884309
DrugRepV_4640	TG-0205221	NA	SARS coronavirus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease	NA	16884309
DrugRepV_4641	5CI-IS-AC	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4642	SPIII-5H	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4643	SPIII-5Cl	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4644	SPIII-5Br	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4645	SPIII-5F	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4646	SPIII-5Me	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4647	SPIII-NA	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4714	Nutlin-3	NA	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	29795047
DrugRepV_4715	Hydroxyzine pamoate	Nervous System	Anxiety | Tension	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	29795047
DrugRepV_4716	Amodiaquine Dihydrochloride	Antiparasitic products, Insectisides and Repellents	Malaria	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	29795047
DrugRepV_4717	Amodiaquine Dihydrochloride Dihydrate	Antiparasitic products, Insectisides and Repellents	Malaria	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	29795047
DrugRepV_4718	Chloroquine Diphosphate	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational, Vet approved	29795047
DrugRepV_4719	Hydroxychloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	29795047
DrugRepV_4720	Saracatinib	Anticancer	Osteosarcoma | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	29795047
DrugRepV_4721	Sotrastaurin	Anticancer	Uveal Melanoma | Richter Syndrome | Prolymphocytic Leukemia | Recurrent Mantle Cell Lymphoma Recurrent Small Lymphocytic Lymphoma	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	29795047
DrugRepV_4722	Acetophenazine Maleate	Nervous System	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	29795047
DrugRepV_4723	Dosulepin Hydrochloride	Nervous System	Psychosis	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	29795047
DrugRepV_4724	Methotrimeprazine Maleate Salt	NA	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	29795047
DrugRepV_4725	N1-(4-pyridyl)-2-chloro-5-nitrobenzamide	NA	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	29795047
DrugRepV_5953	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19918064
DrugRepV_5963	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19918064
DrugRepV_5969	ZX-2401	NA	Rhinovirus 1A | Rhinovirus 30 | Rhinovirus 13 | Rhinovirus 8 | Rhinovirus 2	Dengue virus	New Guinea		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16199098
DrugRepV_7241	Favipiravir	Antiviral	Influenza virus	Yellow fever virus	17D		Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27736754
DrugRepV_7330	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Cytopathic effect (CPE) assay	Decrease	NA	27563890
DrugRepV_7331	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Cytopathic effect (CPE) assay	Decrease	NA	27563890
DrugRepV_7387	SCH16-Ribavirin	NA	NA	Japanese encephalitis virus	P20778		Cytopathic effect (CPE) assay	Decrease	NA	22738253
DrugRepV_7388	SCH16-Mycophenolic acid	NA	NA	Japanese encephalitis virus	P20778		Cytopathic effect (CPE) assay	Decrease	NA	22738253
DrugRepV_7525	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7526	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/MO/14-18949		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7527	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/MO/14-18947		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7528	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/IL/14-18952		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7529	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/IL/14-18956		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7530	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7531	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7532	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7533	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7608	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32438446
DrugRepV_7609	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Cytopathic effect (CPE) assay	Decrease (90 %)	Approved	32438446
DrugRepV_7617	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	SARS-CoV-2 (?CoV/KOR/KCDC03/2020	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	32438446
DrugRepV_7647	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32438446
DrugRepV_7648	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Cytopathic effect (CPE) assay	Decrease (90 %)	Approved	32438446
DrugRepV_7672	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32511355
DrugRepV_7673	ROC-325	NA	NA	SARS Coronavirus-2		NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32511355
DrugRepV_7674	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2		NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	32511355
DrugRepV_7675	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2		NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32511355
DrugRepV_7676	Hycanthone	Antischistosomal	Parasitic infections	SARS Coronavirus-2		NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	32511355
DrugRepV_7677	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	SARS Coronavirus-2		NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32511355
DrugRepV_8325	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	32429580
DrugRepV_8326	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	32429580
DrugRepV_8327	4-ethynyl-2-fluoro-2-deoxyadenosine	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8328	Alovudine	NA	HIV	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	32429580
DrugRepV_8329	5-O-(12-thioethydodecanoyl)FLT	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8330	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32429580
DrugRepV_8331	5-O-(tetradecanoyl)3TC	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8332	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32429580
DrugRepV_8333	5-O-(tetradecanoyl)FTC	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8459	Berberine	NA	Parasitic and fungal infection	Enterovirus	H	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8460	Berberine	NA	Parasitic and fungal infection	Enterovirus	SHZH98	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8461	Berberine	NA	Parasitic and fungal infection	Enterovirus	JS-52	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8462	Berberine	NA	Parasitic and fungal infection	Enterovirus	BrCr	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8463	Pirodavir	NA	Picronavirus infection	Enterovirus	H	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706
DrugRepV_8464	Pirodavir	NA	Picronavirus infection	Enterovirus	SHZH98	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706
DrugRepV_8465	Pirodavir	NA	Picronavirus infection	Enterovirus	JS-52	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706
DrugRepV_8466	Pirodavir	NA	Picronavirus infection	Enterovirus	BrCr	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706